IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)

Type 2 Diabetes Clinical Trial

— IGNITE  

Official title:

Continuous Glucose Monitoring Versus Blood Glucose Monitoring to Optimize Glycemic Outcomes in People With Type 2 Diabetes Following the Virta Treatment Program" (IGNITE: Impact of Glucose moNitoring and nutrItion on Time in rangE Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05516797
• Other study ID #: A22-076
• Status: Completed
• Phase: N/A
• Start date: September 22, 2022
• Est. completion date: March 1, 2024

Study information

• Verified date: September 2023
• Source: HealthPartners Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to learn whether there is a difference in the amount of time glucose (blood sugar) stays within a target range (glucose 70 - 180 mg/dl) when using either continuous glucose monitoring (CGM) or fingerstick blood glucose monitoring (BGM) in people with Type 2 diabetes who participate in the Virta Treatment program.

Description:

The purpose of this three-month, randomized, controlled trial is to compare the difference in change in 14-day CGM-derived TIR (% time with glucose 70-180 mg/dL) from Baseline to 3-months Post-Dietary Change in participants with T2D who are assigned to use either BGM or CGM. The difference in mean blood ketone levels and additional glycemic endpoints will also be compared, and several exploratory endpoints, including medication changes, dietary intake, and body weight will be described. The study also includes a three-month Follow-Up period (months three to six), where participants will remain using their randomly assigned glucose monitoring modality (e.g., BGM or CGM); this period will help assess durability of the results found during the intervention. This study will provide insights into how continuous feedback from CGM affects glycemic outcomes, such as TIR and HbA1c, compared to the standard method of BGM. It is important to understand if the methods of glucose monitoring differ, because greater TIR and lower HbA1c are associated with reduced risk of diabetes complications. While many studies have compared the differences in glycemic outcomes between BGM and CGM, this study compares differences between the two glucose monitoring methods as part of a randomized, controlled intervention in people with T2D where dietary patterns will be adjusted. It is possible that this study will help demonstrate whether the continuous feedback provided by CGM influences adherence to dietary guidance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 178
• Est. completion date: March 1, 2024
• Est. primary completion date: March 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age > 18 years

2. U.S. residence with plans to remain in the U.S. for study duration (for shipping purposes)

3. Diagnosis of T2D

4. HbA1c between 7.5-11.5% documented within 60 days prior to consent

5. Stable diabetes medication regimen and lifestyle patterns (eating and activity) within approximately 90 days prior to consent

6. Using at least one glucose-lowering medication (oral or injectable) for diabetes management at the time of consent; if using insulin, this may include up to a total of three or fewer insulin injections per day (e.g., once or twice daily basal insulin, once or twice daily basal insulin plus one prandial insulin dose, once or twice daily pre-mix insulin, or another combination etc.)

7. English language comprehension

8. Confirmed download of FreeStyle Libre 2 app on personal smartphone with access to WiFi

9. Willing and able to record study data using smartphone, tablet, and/or computer

10. Willing to wear and use study-provided CGM devices for up to 7 months

11. Willing to perform fingersticks to test blood glucose

12. Willing to perform fingersticks to test blood ketones twice daily

13. Eligible to initiate and intention to participate in the dietary changes required as part of the Virta Treatment for at least 7 months

Exclusion Criteria:

1. Type 1 diabetes

2. Currently using an insulin pump or multiple daily injection insulin therapy with >3 insulin injections per day or using bolus injections to cover every meal

3. Currently following a self-reported, very low-carbohydrate eating pattern

4. Currently using a personal CGM or plans to use a personal CGM during the study period

5. Advanced-stage renal, cardiac, hepatic, or other chronic disease

6. History of ketoacidosis

7. Pregnant, lactating, or planned pregnancy

8. Allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin

9. Participation in another interventional trial at the time of enrollment or during the study period

10. Participant is unsuitable for participation due to any cause as determined by Investigators

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Device:
• Continuous Glucose Monitoring (CGM)
Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring

Locations

Country	Name	City	State
United States	Health Partners Institute dba International Diabetes Center	Minneapolis	Minnesota

Sponsors (3)

Lead Sponsor	Collaborator
HealthPartners Institute	Abbott Diabetes Care, Virta Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Difference in change in the CGM-derived metric, Time above range > 250 mg/dL , from Baseline to 3-month Post-Dietary Change period	Time above range > 250 mg/dL	Three (3) months
Other	Difference in change in the CGM-derived metric, Time below range <70 mg/dL , from Baseline to 3-month Post-Dietary Change period	Time below range <70 mg/dL	Three (3) months
Other	Difference in change in the CGM-derived metric, Time below range <54 mg/dL , from Baseline to 3-month Post-Dietary Change period	Time below range <54 mg/dL	Three (3) months
Other	Difference in change in the CGM-derived metric, Mean sensor glucose, from Baseline to 3-month Post-Dietary Change period	Mean sensor glucose	Three (3) months
Other	Difference in change in the CGM-derived metric, % Coefficient of variation, from Baseline to 3-month Post-Dietary Change period	% Coefficient of variation	Three (3) months
Other	Difference in change in the CGM-derived metric, Mean amplitude of glucose excursion, from Baseline to 3-month Post-Dietary Change period	Mean amplitude of glucose excursion	Three (3) months
Primary	Difference in change in 14-day CGM-derived TIR	Difference in change in 14-day CGM-derived TIR (% time with glucose 70-180 mg/dL) from Baseline to 3-month Post-Dietary Change period between participants with T2D who are randomized to use either BGM or CGM as part of Virta Treatment.	Three (3) months
Secondary	Difference in 90-day mean blood ketone levels	Difference in 90-day mean blood ketone levels between BGM and CGM arms	Three (3) months
Secondary	Difference in change in the CGM-derived metric, Time above range > 180 mg/dL, from Baseline to 3-month Post-Dietary Change period	Time above range > 180 mg/dL	Three (3) months
Secondary	Difference in percent of participants reaching CGM-derived consensus targets	Difference in percent of participants reaching CGM-derived consensus targets at the end of the 3-month Post-Dietary Change period between BGM and CGM arms	Three (3) months
Secondary	Difference in Change in HbA1c	Difference in Change in HbA1c from Baseline to the end of the 3-month Post-Dietary Change period between BGM and CGM arms	Three (3) months